Quantcast
Close Window
   
Welcome :o)
Welcome to another year exposing the harms of Johnson & Johnson products and the executives that care more about money than human health...
 
There really is a highly effective way to put an end to mass tort lawsuits: GET JOHNSON & JOHNSON AND SUBSIDIARY KNOWN DEFECTIVE, HARMFUL AND/OR TOXIC PRODUCTS OFF THE GLOBAL MARKET
 
This work is 100% independent. I am NOT a victim, NOT a lawyer, NOT paid by anyone other than visitors to the site. And no, I do not own any stock in Johnson & Johnson.
 
Emily.
HomeAbout

Content List
100+ articles of harm and corruption by Johnson & Johnson and subsidiary products.
Click for content list...

Glad to see you :o)
March 2017 marks FIVE YEARS of work exposing harm, corruption and massive costs of flood of KNOWN HARMFUL Johnson & Johnson products.
 
This web site currently has the attention of:
click link to validate IP address through whatismyipaddress.com
 
US GOVERNMENT:
US Senate
US Department of Defense
US Department of Justice
US Homeland Security
 
GLOBAL FINANCIAL INSTITUTIONS:
...including many Johnson & Johnson shareholders ;o)
 
Vanguard
The Bank of New York Mellon Corp
Lloyds Banking Group PLC
Royal Bank of Canada
Bank of America
Harris Trust & Savings Bank
Deutsche Bank
Macquarie Bank
PNC Bank
Crédit Agricole Bank
Royal Bank of Scotland
Raymond James Financial
BlackRock Financial Management
...and many, many more from all over the world ;o)
 
I am not paid by lawyers, doctors, etc - ONLY by visitors to the web site, the PEOPLE I am working for, PEOPLE like you. Currently reduced to only a part-time job, I donate the remainder of my time to take care of all the work involved in maintaining the site by doing the research, search engine optimized content, responding to victim emails and social media to create awareness among consumers to prevent new injuries as well as continue increasing awareness among Johnson & Johnson shareholders and global health organizations. Feel free to browse list of notable visitors to the web site.
 
God Bless You and Yours and keep you safe from harm,
Emily
 
Please send financial support to keep this very important GLOBAL consumer safety effort going...
 
Enter any amount in GiftBox below or PayPal to Email:
 
emily@johnsonandtoxin.com
 
$.00   
 
Sponsored in part by...
Examining Medicine An in-depth comprehensive, frequently updated look at extreme risks and permanent brain damage caused by psychiatric drugs.
----- / / -----
Fiddaman Blog Bob Fiddaman has been writing about the dangers of antidepressants since 2006. In 2011 he was presented with two human rights awards from the Citizens Commission on Human Rights.
----- / / -----
Special Needs Advocate Power Join me as we work hard to ensure what our very special children need.

Letter to CitiCorp Matthew Dodds RE: $JNJ 3rd quarter 2013 Conference Call
Since Orsinger danced around issues causing delays in completion of Synthes acquisition and basically said nothing, I figured I'd give him a real answer.

Keywords: johnson & johnson, JNJ, j&j, matthew dodds, citicorp, financial analyst, orsinger
Date Created/Edited: October 17, 2013
 
Matthew Dodds
Citigroup, Inc.
Director Medical Supplies & Technology
399 Park Avenue
New York, New York 10043
United States
 
RE: Johnson & Johnson 3rd Quarter Teleconference: 14 October 2013
 
Dear Matthew Dodds,
 
My name is Emily Patterson. I am the creator of and researcher for a web site called Johnson and Toxin. After reading the transcript of the 3rd quarter 2013 teleconference with Johnson & Johnson Vice President of Finance, Dominic Caruso and Johnson & Johnson Worldwide Chairman of DePuy Synthes companies, Michel Orsinger, I felt your questions required a little more realistic clarification.
 
You have a very valid concern regarding why the Synthes acquisition, which started in the last quarter of 2012, is costing additional money and continues to drag on almost a year later. I agree that it would be very nice if Johnson & Johnson were able to give a rock-solid time frame for completion of this long, drawn-out process - or at least clarify what is taking so long and costing so much in addition to the original acquisition price.
 
As you may be aware, not long before the Johnson & Johnson acquisition of Synthes, a major corruption scandal regarding bone cement, a Synthes Norian product, had recently been partially resolved. Michel Orsinger, as president of Norian Corporation, signed the Synthes Norian Settlement Agreement on 20 September, 2010. Four of the indicted managers served prison sentences and $100,000 fines for the scandal.
 
Lawsuits have begun for the three known dead victims of illegally testing a new procedure on humans when animal studies had already proven the increased risk of death from using the product injected into the spine. I'm sure Mr. Orsinger, as Worldwide Chairman of DePuy Synthes is very busy with Norian, now a subsidy of Kensey Nash, trying to figure out how to handle these lawsuits.
 
Mr. Orsinger, as Worldwide Chairman of DePuy Synthes, is likely also very busy wrapping up misbranding and customer complaint reporting issues at Synthes. These issues were brought to Mr. Orsigner's attention with a Warning Letter by the United States Food and Drug Administration which states numerous violations in misbranding of currently available Johnson & Johnson DePuy Synthes products. In addition, the FDA Warning Letter clearly shows inadequate handling of customer complaints with regard to registering complaints with the FDA for review in violation of FDA regulations.
 
It is my hope that these issues will be brought under control as soon as possible. However, litigation, settlements, rebranding and creating an FDA compliant customer complaint process takes an unknown amount time and money to resolve so any forward-thinking completion date or final total cost is unavailable at this time, which is likely why Mr. Orsinger gave you a complete and total non-answer during the 2013 3rd quarter conference call.
 
I hope this provided a more detailed explanation for your concerns,
Emily Patterson
 
cc:
Alex Gorsky
Dominic Caruso
Michel Orsinger
Barack Obama

Special Sections....
 
Mesh Files
Baby Powder (talc) Files
Risperdal Files
Levaquin Files
Xarelto Files
Hips Files
Letters to Shareholders
SEC Lawsuits Files

 
Recent Content....
The Fastest Growing Segment of Johnson & Johnson Is... (2016, November 15)
Growing over 29% in 2016, this is definitely the fastest growing segment of Johnson & Johnson!
johnson & johnson, J&J, JNJ, 2016, lawsuit, lawsuits, tort, liability
 
Third Quarter 2016 Lawsuits Against Johnson & Johnson Still Exploding! Now 99,000! (2016, November 15)
Growing every quarter, lawsuits against Johnson & Johnson in United States alone are now well over 99,000.
talc, risperdal, asr, hip, baby powder, tvt, mesh, lawsuit
 
The Difference Between Guinea Pig and Cash Cow (2016, September 27)
People keep saying pharma is using us as 'guinea pigs'. Uh, not quite. Take a minute to learn the difference between a 'guinea pig' and a 'cash cow'.
guinea pig, immunization, vaccination, profit, harm, autism, disability, asthma
 
Johnson & Johnson Victims at Risk of RE-Victimization (2016, August 22)
If you are currently a victim of a known harmful Johnson & Johnson subsidiary product and have high medical needs due to your injuries, you are at increased risk of becoming a victim of another known harmful Johnson & Johnson subsidiary product.
jnj, johnson and johnson, johnson & johnson, victim, mesh, hip, levaquin, risperdal
 
Wealthy Most at Risk for Harm by Johnson & Johnson and Subsidiary Products (2016, August 22)
If you make over $100,000 a year, you are far more likely than lower incomes to become a victim of a Johnson & Johnson and/or subsidiary product.
healthcare, cost, co-pay, risk, deductable, insurance, victim, salary
 
Second Quarter 2016 Lawsuits Against Johnson & Johnson Leap Again From 82,200 to 90,700 (2016, August 4)
Growing every quarter, lawsuits against Johnson & Johnson in United States alone are now well over 90,700.
talc, risperdal, asr, hip, baby powder, tvt, mesh, lawsuit
 
Johnson & Johnson Animas Defective Diabetes Devices (2016, August 4)
Gosh and golly gee willikers, yet another Johnson & Johnson subsidiary, Animas, totally sucks, jah?
Johnson and Johnson, Johnson & Johnson, animas, vibe, diabetes, insulin, device, pump
 
Johnson & Johnson Ethicrap, I Mean EthiCON, More JNJ JUNK (2016, July 25)
As I've mentioned, Johnson & Johnson has so many bad products I have to put a bunch in each article now to try to keep up. Now for EthiCON crap.
Johnson and Johnson, Johnson & Johnson, ethicon, harmonic ace, morcellator, physiomesh, secure strap, stapler
 
Johnson and Johnson Janssen Xarelto Slaughter (2016, July 8)
Overstating benefits, downplaying (or not disclosing) risks. Xarelto by Johnson and Johnson Janssen killing people left and right. Over 500 DEAD, 7,100 lawsuits already. Lovely, eh?
false, marketing, death, dead, xarelto, FDA, lawsuit, Janssen
 
This Convinced THREE Juries That Johnson and Johnson Talc Increases Ovarian Cancer (2016, May 14)
One very simple fact convinced THREE juries that Johnson & Johnson talc increases risk of developing ovarian cancer.
Johnson and Johnson, Johnson & Johnson, baby, powder, cancer, lawsuit, ovarian, talc
 

 


 
Resources:
1. TRANSCRIPT (2013, October 15). Johnson & Johnson's Management Discusses Q3 2013 Results - Earnings Call Transcript. Seeking Alpha. Retrieved from http://seekingalpha.com/article/1746172-johnson-and-johnsons-management-discusses-q3-2013-results-earnings-call-transcript?page=11&p=qanda&l=last
 
2. Roslyn Rudolph (2010, September 20). Synthes Norian Settlement Agreement. Scribd. Retrieved from http://www.scribd.com/doc/56855255/Synthes-Norian-Settlement-Agreement
 
3. David Sell (2011, December 14). Fourth ex-Synthes executive sentenced in illegal use of bone cements. Philly.com. Retrieved from http://www.philly.com/philly/business/20111214_Fourth_ex-Synthes_executive_sentenced_in_illegal_use_of_bone_cements.html
 
4. Kirk Sooter (2012, March 7). Warning Letter by the United States Food and Drug Administration. United States Food and Drug Administration. Retrieved from www.fda.gov/ICECI/EnforcementActions/WarningLetters/2012/ucm294688.htm
 
All contents Copyright © 2012-2016 Emily Patterson / Johnson and Toxin. All rights reserved.
 
Web Site and Admin Info:
Home
About
Contact
Disclaimers
Privacy Policy
Site Statistics
Site Resources
Financial Disclosure

 
Recently Posted:
2015 Johnson & Johnson US Lawsuit Update: Jump from 48,500 to 56.500
 
Johnson & Johnson Plans to Expand Healthcare Cost Crisis and Product Liability in Asia
 
Who REALLY Pays for Drug Development? US TAXPAYERS - $21 BILLION for fiscal year 2014
 
Johnson & Johnson Janssen Xarelto Marketed In Violation of FDA Regulations
 
Johnson & Johnson Destroys Thousands of Files Related to Vaginal Mesh
 
Johnson & Johnson: The Global Lawsuit Company


 
 
Most Popular:
The Ever-Growing Number of Lawsuits Against Johnson & Johnson
 
Johnson & Johnson Credo Analysis
 
Johnson & Johnson $4 Billion for DePuy Hip Harm in U.S., With Lawsuits in at Least 4 More Countries